By: Dr Susan Leonera-Salazar and Dr Ramon Joel Seastres

The HIV epidemic in the Philippines is marked by persistent challenges in diagnosis, treatment, and viral suppression, compounded by social stigma and systemic barriers. This discussion synthesizes the evidence from the executive HIV summary and supporting research to outline the current state, key obstacles, and actionable strategies for progress.

1. Current State and Gaps

Diagnosis: Only 57% of estimated People Living with HIV (PLHIV) are diagnosed, far below the UNAIDS 95% target. Stigma, discrimination, and limited access to Testing, especially in remote areas, is a major deterrent.

Treatment: Of those diagnosed, 66% are on antiretroviral therapy (ART), with a high loss- to-follow-up rate (22%). Barriers include lack of awareness, financial constraints, and logistic issues.

Viral Suppression: Only 47% of PLHIV on ART achieve viral suppression, with just 56% undergoing viral load testing in the past year. Regional disparities are significant, with areas like BARMM, Eastern Visayas, and Northern Mindanao showing particularly low coverage.

2. Social and Structural Barriers

Stigma and Discrimination: Social stigma, especially against men who have sex with men (MSM), transgender women, and people who inject drugs (PWID), is pervasive. Over 70% of HIV cases are among MSM, yet more than 75% have never been tested. Stigma is rooted in cultural, religious, and legal factors, leading to delays in testing, treatment avoidance, and internalized shame.

Legal Protections: While Republic Act 11166 provides anti-discrimination provisions, enforcement is inconsistent and societal attitudes remain a barrier. Legal frameworks offer some empowerment but are insufficient to fully address stigma.

Healthcare System Challenges: Many healthcare providers lack training in culturally competent care for MSM and other vulnerable groups. Facilities often do not offer youth- friendly or gender-sensitive services, and there are gaps in the HIV care cascade, particularly in retention and viral suppression.

3. Vulnerable Populations

Children, Adolescents, Pregnant Women, Transgender Women, and PWID: These groups have lower diagnosis and treatment coverage due to unique barriers such as youth-friendly services, gender-based discrimination, and limited access to care.

Geographic Disparities: Uneven access to healthcare services across regions exacerbates the epidemic, with some areas experiencing higher loss to follow-up and lower viral load testing rates.

4. Key Strategies and Recommendations

Expand HIV Testing Services

Implement community-based and routine healthcare integrated testing, especially in underserved regions. Distribute affordable or free self-testing kits to increase accessibility and reduce stigma.

Increase ART (Antiretroviral therapy) Coverage.

Scale up treatment hubs and primary HIV care facilities Provide free or subsidized ART and strengthen adherence support (peer counselling, mobile reminders)

Enhance Viral Load Testing and Suppression

Invest in infrastructure and consistent supply of testing kits Train healthcare workers and implement regional strategies to address disparities.

Address Stigma and Discrimination

Launch nationwide awareness campaigns and enforce anti-discrimination laws. Engage community leaders and influencers to foster acceptance.

Focus on Vulnerable Populations

Develop tailored interventions and expand access to pre-exposure prophylaxis (PrEP) for high-risk groups. Provide gender-sensitive and youth-friendly services.

Strengthen Data Collection and Monitoring

Improve surveillance systems for accurate, timely data to guide resource allocation and monitor progress toward the 95-95-95 UNAIDS target.

5. Cost-Benefit Analysis

Costs
Infrastructure investment (ie., treatment hubs, testing facilities)
Operational costs (outreach, adherence support)
Policy implementation (ie. awareness campaigns, tailored interventions)

Benefits
Improved health outcomes: reduced transmission, better quality of life, and fewer AIDS- related deaths
Economic gains: lower healthcare costs, increased productivity, and reduced absenteeism
Social impact: reduced stigma, improved mental health, and greater social integration for PLHIV

6. Research Limitations and Future Directions

Most research is urban-focused, with rural areas underrepresented. Self-reporting and socio- economic biases may affect findings. There is a need for more detailed intervention strategies and implementation research, especially in rural and marginalized communities. Future efforts should prioritize community-based, culturally sensitive interventions, healthcare provider training, and legal enforcement to reduce disparities and improve outcomes.

On the present trajectory, the country remains far off the path to 95-95-95 by 2030. These are very steep, especially for viral suppression, given current viral load testing coverage (56%) and high loss to follow-up (22%). Achieving the targets is still possible but only with rapid, nationwide acceleration across three levers executed in parallel:

i. Diagnose: scale community testing and self-testing to add 7-8 percentage points per year, prioritising regions with lowest coverage (ie. BARMM, Eastern Visayas, Northern Mindanao) and key populations

ii. Treat: expand treatment hubs, remove financial/ logistical barriers, and cut loss to follow- up through differentiated service delivery and adherence support to gain 6 percentage points per year

iii. Suppress: invest in viral load access, turnaround time, and regimen optimisation; deploy intensive adherence and stigma-reduction interventions to lift suppression by 10 percentage points per year

Key execution risks and mitigations

i. Stigma and Discrimination: depress testing, linkage, and adherence. By enforcing RA 11166, running sustained community-led campaigns, and training providers in culturally competent care.

ii. Service access gaps: geographic disparities and facility constraints. Using mobile and outreach models, telemedicine, multi-month dispensing, and integration with primary care and maternal-child health

iii. Monitoring constraints: suboptimal VL (viral load) testing and data systems. To ensure viral load testing commodities, decentralize platforms, and strengthen surveillance for targeted resource allocation.

Given the current baselines and gaps, reaching 95-95-95 by 2030 demands immediate, coordinated scale-up of testing, ART coverage and retention, and viral load-driven suppression, with a decisive focus on high-burden regions and vulnerable groups. Without acceleration, the targets are unlikely to be met on time.

Source:
1. Department of Health Epidemiology Bureau: HIV and AIDS Surveillance of the Philippines April-June 2025
2. HIV in the Philippines: A persisting public health crisis closely tied to social stigma: Brown Undergraduate Journal of Public Health, Issue 3, 21 March 2024